EQRx, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Melanie I. Nallicheri
- Full Time Employees
- 362
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Hampshire Street Cambridge MA United States of America 02139
- IPO Date
- Jun 3, 2021
- CIK
- 0001843762
- Website
- eqrx.com
- Similar Companies
- Business
- EQRx, Inc. (NASDAQ: EQRX) operates as a clinical-stage biotechnology company focused on discovering, developing and commercializing medicines for oncology and immune-inflammatory diseases. The company maintains a pipeline of novel drug candidates including aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer; sugemalimab, an anti-programmed cell death-ligand 1 (PD-L1) antibody; lerociclib (EQ132), a selective cyclin-dependent kinase 4/6 inhibitor; nofazinlimab, an anti-programmed death-1 (PD-1) antibody for liver and hepatocellular carcinoma; EQ121, a selective Janus kinase-1 inhibitor for ankylosing spondylitis, atopic dermatitis and rheumatoid arthritis; and additional preclinical and discovery-stage assets targeting high-burden therapeutic areas. Founded in 2019 and headquartered at 50 Hampshire Street in Cambridge, Massachusetts, EQRx conducts operations primarily in the United States with global partnerships supporting its pipeline advancement. In November 2023, Revolution Medicines, Inc. completed an all-stock acquisition of EQRx, converting each EQRx share into 0.1112 shares of Revolution Medicines common stock and delisting EQRx from Nasdaq, while adding over $1 billion in net cash to Revolution Medicines' balance sheet to support its RAS-targeted oncology programs; EQRx programs were subsequently wound down with intellectual property returned to original partners.
Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
Should You Buy EQRx (EQRX) Ahead of Earnings?
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines
Best Penny Stocks To Watch After Fitch Downgrade? 3 For Your List
EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders
Revolutin Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D
OmniAb Reports First Quarter 2023 Financial Results and Business Highlights
EQRx, Inc. (EQRX) Q1 2023 Earnings Call Transcript
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
New Strong Buy Stocks for April 12th
AI Opportunities in Personalised Medicine 2023: Dawn of the AI Era Set to Unlock New Understanding of Disease Pathologies - ResearchAndMarkets.com
OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
Here's Why EQRx, Inc. (EQRX) is Poised for a Turnaround After Losing 23% in 4 Weeks
Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer
EQRx, Inc. (EQRX) Q3 2022 Earnings Call Transcript